Stock C4XD C4X DISCOVERY HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials C4X Discovery Holdings plc

Equities

C4XD

GB00BQQ2RV18

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:46:00 2024-04-25 am EDT 		5-day change 1st Jan Change
12 GBX +27.32% Intraday chart for C4X Discovery Holdings plc -.--% +33.33%
Apr. 25 Norcros sells Johnson Tiles UK; Trifast trading well AN
Apr. 25 C4X Discovery Set for Friday Delisting from London Bourse's AIM MT

Valuation

Fiscal Period: Juli 2018 2019 2020 2021 2022 2023
Capitalization 1 45.39 26.87 20.05 71.41 61.43 50.93
Enterprise Value (EV) 1 39.81 24.49 14.81 54.72 57.08 47.13
P/E ratio -40 x -2.47 x -2.28 x -16.1 x -7.51 x -4.57 x
Yield - - - - - -
Capitalization / Revenue 6.43 x - - 12.7 x 22.8 x 29.8 x
EV / Revenue 5.64 x - - 9.7 x 21.2 x 27.6 x
EV / EBITDA -16.9 x -1.82 x -1.58 x -9.46 x -5.44 x -3.52 x
EV / FCF -44.2 x -2.37 x -4.49 x -18.1 x -5.44 x -14.5 x
FCF Yield -2.26% -42.2% -22.3% -5.51% -18.4% -6.91%
Price to Book 5.55 x 3.83 x 2.73 x 3.72 x 5.2 x 7.8 x
Nbr of stocks (in thousands) 46,555 57,793 108,366 226,713 229,232 252,120
Reference price 2 0.9750 0.4650 0.1850 0.3150 0.2680 0.2020
Announcement Date 12/11/18 1/7/20 12/18/20 12/15/21 12/19/22 12/18/23
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net sales 1 7.064 - - 5.642 2.699 1.71
EBITDA 1 -2.355 -13.46 -9.393 -5.782 -10.49 -13.38
EBIT 1 -2.533 -13.64 -9.566 -5.893 -10.52 -13.41
Operating Margin -35.86% - - -104.45% -389.85% -784.44%
Earnings before Tax (EBT) 1 -2.526 -13.62 -9.579 -5.907 -10.53 -13.42
Net income 1 -1.135 -10.91 -7.789 -3.844 -8.16 -11.11
Net margin -16.07% - - -68.13% -302.33% -649.77%
EPS 2 -0.0244 -0.1882 -0.0810 -0.0196 -0.0357 -0.0442
Free Cash Flow 1 -0.9011 -10.33 -3.3 -3.016 -10.49 -3.256
FCF margin -12.76% - - -53.47% -388.76% -190.39%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/11/18 1/7/20 12/18/20 12/15/21 12/19/22 12/18/23
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 5.58 2.38 5.24 16.7 4.35 3.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.9 -10.3 -3.3 -3.02 -10.5 -3.26
ROE (net income / shareholders' equity) -13.2% -144% -103% -28.1% -52.5% -121%
ROA (Net income/ Total Assets) -16.5% -96.3% -65.3% -23.7% -36.6% -71.8%
Assets 1 6.872 11.33 11.92 16.2 22.32 15.48
Book Value Per Share 2 0.1800 0.1200 0.0700 0.0800 0.0500 0.0300
Cash Flow per Share 2 0.1200 0.0400 0.0500 0.0800 0.0200 0.0200
Capex 1 0.04 0.05 0.01 0.02 0.04 0.02
Capex / Sales 0.62% - - 0.35% 1.37% 1.05%
Announcement Date 12/11/18 1/7/20 12/18/20 12/15/21 12/19/22 12/18/23
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
C4X DISCOVERY HOLDINGS PLC Stock C4X Discovery Holdings plc
+33.33% 37.99M
MODERNA, INC. Stock Moderna, Inc.
+29.03% 48.16B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.10% 41.73B
LONZA GROUP AG Stock Lonza Group AG
+43.45% 41.03B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.48% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.74% 18.96B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+9.06% 12.92B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.01% 12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.51% 11.77B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. C4XD Stock
  4. Financials C4X Discovery Holdings plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW